The fulminant index: A method of rapidly differentiating fulminant type 1 diabetes from diabetic ketoacidosis.

Diabetes Metab Res Rev

Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Published: March 2022

Aims And Objectives: Fulminant type 1 diabetes (FT1D) could present diabetes ketoacidosis (DKA) at early onset. It is crucial to identify FT1D from DKA manifestations in time at clinical practice. This study was aimed at investigating whether the fulminant index (FI), encompassing plasma glucose (PG) to glycated haemoglobin (HbA1c) ratio (PG/HbA1c), serum potassium ion (K ) to HbA1c ratio (K /HbA1c) and serum sodium ion (Na ) multiplied by HbA1c (Na *HbA1c), is a feasible indicator for early FT1D diagnosis.

Materials And Methods: A total of 78 subjects were enroled, including 40 FT1D patients and 38 non-FT1D patients with DKA. We utilised receiver operating characteristic (ROC) curve analysis to determine the FI cut-off values between FT1D and non-FT1D groups and examined efficacies of FI based on statistics.

Results: ROC curve analyses showed that the maximum Youden's index for PG/HbA1c bonding to a cut-off value of 4.389, with the sensitivity of 75.0% and specificity of 81.6% in identifying FT1D from DKA. And optimal K /HbA1c cut-off value was 0.728 with a sensitivity of 90.0% and specificity of 84.2%. For Na *HbA1c, the best cut-off value was 923.65, and its sensitivity and specificity were 85% and 73.7%, respectively.

Conclusions: These results suggested FI could work as a valid and convenient indicator for differentiating FT1D from initial DKA patients. FI (K /HbA1c) presented the best efficacy as an independent index.

Download full-text PDF

Source
http://dx.doi.org/10.1002/dmrr.3501DOI Listing

Publication Analysis

Top Keywords

fulminant type
8
type diabetes
8
ft1d dka
8
hba1c ratio
8
roc curve
8
ft1d
7
dka
5
fulminant
4
fulminant method
4
method rapidly
4

Similar Publications

Acute liver failure (ALF) is a fulminant clinical syndrome that usually leads to multiple organ failure and high mortality. Macrophages play a crucial role in the initiation, development, and recovery of ALF. Targeting macrophages through immunotherapy holds significant promise as a therapeutic strategy.

View Article and Find Full Text PDF

A 64-year-old man with cirrhosis was diagnosed with unresectable hepatocellular carcinoma and treated with a combination of durvalumab and tremelimumab. The patient had no history of diabetes mellitus. Three weeks later, the patient developed general fatigue, dry mouth, and polyuria.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitor (ICI) therapy has revolutionized cancer treatment but is associated with fulminant type 1 diabetes mellitus (FT1DM). Our study aims to investigate the association between ICI therapy and FT1DM using the FDA Adverse Event Reporting System (FAERS) database.

Methods: We conducted a retrospective analysis from the first quarter of 2004 to the first quarter of 2023.

View Article and Find Full Text PDF

Brugada phenocopy in fulminant eosinophilic myocarditis: a case series.

Eur Heart J Case Rep

December 2024

Department of Cardiology, Tsuyama Chuo Hospital, 1756 Kawasaki, Tsuyama, Okayama 708-0841, Japan.

Background: Brugada phenocopy (BrP) is a condition that induces reversible Brugada-like electrocardiographic (ECG) changes in patients without true Brugada syndrome. We present two cases of fulminant eosinophilic myocarditis that showed Type 1 Brugada ECG changes in the early phase of the clinical course.

Case Summary: Case 1 was a 76-year-old man who developed fulminant eosinophilic myocarditis with ventricular tachycardia while hospitalized for heart failure.

View Article and Find Full Text PDF

BACKGROUND Herpes simplex virus (HSV) is a rare cause of hepatitis. HSV hepatitis can be life-threatening due to its rapid progression to liver failure if not treated on time. It affects primarily immunocompromised individuals but can also present in immunocompetent hosts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!